Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06173531 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 8 more changesShow less
    • Results posted: Oct 15, 2026
    • Trial completed
    • Primary completion date changed from estimate of Oct 2025 to Aug 19, 2025
    • Enrollment target: estimated 170 to confirmed 175
    • Eligibility criteria shortened, about 109 words
    • Secondary endpoints: 2 to 4
    • Site details revised at 13 of 30 sites
    • Publications: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv22
  3. Primary completion date: May 2026 to Oct 2025
    • Study completion date: Jun 2026 to Nov 2025
    • Eligibility criteria expanded, about 25 words
    v21
  4. 2 versions Re-verified since Jul 1, 2025, no change to tracked fieldsv19-v20
  5. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 33 to 30
    v18
Show 16 earlier versionsHide 16 earlier versions
  1. Study sites: 31 to 33v17
  2. Study sites: 26 to 31v16
  3. Study sites: 25 to 26v15
  4. Study sites: 23 to 25v14
  5. Re-verified, no change to tracked fieldsv13
  6. Study sites: 22 to 23v12
  7. Study sites: 17 to 22v11
  8. Study sites: 15 to 17v10
  9. Study sites: 11 to 15v9
  10. Study sites: 10 to 11v8
  11. Study sites: 7 to 10v7
  12. Study sites: 3 to 7v6
  13. Re-verified, no change to tracked fieldsv5
  14. Site details revised at 1 of 3 sitesv4
  15. Trial status: Enrolling by Invitation to Recruiting
    • Site details revised at 3 of 3 sites
    v3
  16. Study sites: 2 to 3v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
Trial Details
NCT Number NCT06173531
Lead Sponsor ACADIA Pharmaceuticals Inc.
Conditions
(from sponsor)		 Hyperphagia in Prader-Willi Syndrome
Enrollment 175 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov